PMID- 33111626
OWN - NLM
STAT- MEDLINE
DCOM- 20211014
LR  - 20220216
IS  - 1532-8457 (Electronic)
IS  - 1043-4542 (Print)
IS  - 1043-4542 (Linking)
VI  - 38
IP  - 1
DP  - 2021 Jan/Feb
TI  - Commonly Reported Adverse Events Associated With Pediatric Immunotherapy: A 
      Systematic Review From the Children's Oncology Group.
PG  - 16-25
LID - 10.1177/1043454220966590 [doi]
AB  - BACKGROUND: Immunotherapy is a new and promising approach to treating pediatric 
      cancers. These types of therapies have unique mechanisms of action for 
      identifying and fighting cancer, as compared with traditional chemotherapy, and 
      therefore are associated with different therapy-related adverse events (AEs). The 
      purpose of this systematic review was to review available evidence to: (a) 
      identify commonly reported AEs associated with immunotherapy agents frequently 
      used in pediatric oncology and (b) generate recommendations for nursing practice. 
      METHOD: A clinical question was developed and used to guide the systematic 
      literature review. Five immunotherapy agents (dinutuximab, blinatumomab, 
      rituximab, inotuzumab ozogamicin, brentuximab vedotin) were selected for 
      inclusion secondary to their high relevance to pediatric oncology. A literature 
      search was conducted to locate articles published between January 1, 2003 and 
      October 31, 2018. RESULTS: Seventeen articles met eligibility criteria for 
      inclusion and were evaluated using the Grading of Recommendations Assessment, 
      Development, and Evaluation criteria. The most commonly reported AEs for the 
      selected immunotherapy agents were identified and summarized. Strong 
      recommendations are made for nurses to become familiar with the unique AE 
      profiles associated with individual immunotherapy agents. Agent-specific 
      recommendations for nursing practice regarding AEs associated with dinutuximab 
      and rituximab were generated. CONCLUSIONS: Immunotherapy is rapidly emerging as 
      an effective therapy for pediatric cancers. Nurses need to be aware of the 
      breadth of agent-specific, immunotherapy-related AEs to appropriately monitor and 
      manage patients receiving these therapies. Additional work is needed to 
      confidently profile immunotherapy-related AEs in pediatric oncology and to 
      develop agent-specific educational materials for patients/families.
FAU - Withycombe, Janice S
AU  - Withycombe JS
AUID- ORCID: 0000-0002-3042-9049
AD  - Clemson University, Clemson, SC, USA.
AD  - Bi-Lo Charities Children's Cancer Center, Greenville, SC, USA.
FAU - Carlson, Aimee
AU  - Carlson A
AUID- ORCID: 0000-0003-3634-4094
AD  - Cleveland Clinic Children's Hospital, Cleveland, OH, USA.
FAU - Coleman, Carly
AU  - Coleman C
AD  - Cohen Children's Medical Center, New Hyde Park, NY, USA.
FAU - Leslie, Sharon L
AU  - Leslie SL
AUID- ORCID: 0000-0002-6597-977X
AD  - Emory University, Atlanta, GA, USA.
FAU - Skeens, Micah
AU  - Skeens M
AUID- ORCID: 0000-0001-6786-8128
AD  - Nationwide Children's Hospital, Columbus, OH, USA.
FAU - Tseitlin, Hanna
AU  - Tseitlin H
AD  - McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, 
      Canada.
FAU - Duffy, Elizabeth A
AU  - Duffy EA
AUID- ORCID: 0000-0001-5038-803X
AD  - University of Michigan School of Nursing, Ann Arbor, MI, USA.
LA  - eng
GR  - U10 CA180886/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Systematic Review
DEP - 20201028
PL  - United States
TA  - J Pediatr Oncol Nurs
JT  - Journal of pediatric oncology nursing : official journal of the Association of 
      Pediatric Oncology Nurses
JID - 8917825
SB  - IM
MH  - Child
MH  - Humans
MH  - *Immunotherapy/adverse effects
MH  - Medical Oncology
MH  - *Neoplasms/drug therapy
PMC - PMC8822201
OTO - NOTNLM
OT  - adverse events
OT  - immunotherapy
OT  - pediatric oncology
OT  - toxicities
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2020/10/29 06:00
MHDA- 2021/10/15 06:00
PMCR- 2021/10/28
CRDT- 2020/10/28 08:44
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/10/15 06:00 [medline]
PHST- 2020/10/28 08:44 [entrez]
PHST- 2021/10/28 00:00 [pmc-release]
AID - 10.1177_1043454220966590 [pii]
AID - 10.1177/1043454220966590 [doi]
PST - ppublish
SO  - J Pediatr Oncol Nurs. 2021 Jan/Feb;38(1):16-25. doi: 10.1177/1043454220966590. 
      Epub 2020 Oct 28.